Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute

Risa Haruki, Takuya Kimura, Hitomi Iwasaki, Kana Yamada, Ikuo Kamiyama, Mitsutomo Kohno, Kazuaki Taguchi, Saori Nagao, Toru Maruyama, Masaki Otagiri, Teruyuki Komatsu

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core-shell structured hemoglobin-albumin cluster designated as "HemoAct", is an O 2 -carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125 I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.

Original languageEnglish
Article number12778
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - 2015 Jul 29

Fingerprint

Blood Substitutes
Serum Albumin
Albumins
Hemoglobins
Erythrocytes
Safety
Erythrocyte Transfusion
Vasoconstriction
Viscosity
Intravenous Administration
Half-Life
Blood Cells
Pharmacokinetics
Hemodynamics
Blood Pressure
Control Groups
Serum

ASJC Scopus subject areas

  • General

Cite this

Haruki, R., Kimura, T., Iwasaki, H., Yamada, K., Kamiyama, I., Kohno, M., ... Komatsu, T. (2015). Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute. Scientific Reports, 5, [12778]. https://doi.org/10.1038/srep12778

Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute. / Haruki, Risa; Kimura, Takuya; Iwasaki, Hitomi; Yamada, Kana; Kamiyama, Ikuo; Kohno, Mitsutomo; Taguchi, Kazuaki; Nagao, Saori; Maruyama, Toru; Otagiri, Masaki; Komatsu, Teruyuki.

In: Scientific Reports, Vol. 5, 12778, 29.07.2015.

Research output: Contribution to journalArticle

Haruki, R, Kimura, T, Iwasaki, H, Yamada, K, Kamiyama, I, Kohno, M, Taguchi, K, Nagao, S, Maruyama, T, Otagiri, M & Komatsu, T 2015, 'Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute', Scientific Reports, vol. 5, 12778. https://doi.org/10.1038/srep12778
Haruki R, Kimura T, Iwasaki H, Yamada K, Kamiyama I, Kohno M et al. Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute. Scientific Reports. 2015 Jul 29;5. 12778. https://doi.org/10.1038/srep12778
Haruki, Risa ; Kimura, Takuya ; Iwasaki, Hitomi ; Yamada, Kana ; Kamiyama, Ikuo ; Kohno, Mitsutomo ; Taguchi, Kazuaki ; Nagao, Saori ; Maruyama, Toru ; Otagiri, Masaki ; Komatsu, Teruyuki. / Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute. In: Scientific Reports. 2015 ; Vol. 5.
@article{877ca1bc4fcc4108b6cf227c37265027,
title = "Safety Evaluation of Hemoglobin-Albumin Cluster {"}HemoAct{"} as a Red Blood Cell Substitute",
abstract = "A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core-shell structured hemoglobin-albumin cluster designated as {"}HemoAct{"}, is an O 2 -carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125 I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.",
author = "Risa Haruki and Takuya Kimura and Hitomi Iwasaki and Kana Yamada and Ikuo Kamiyama and Mitsutomo Kohno and Kazuaki Taguchi and Saori Nagao and Toru Maruyama and Masaki Otagiri and Teruyuki Komatsu",
year = "2015",
month = "7",
day = "29",
doi = "10.1038/srep12778",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute

AU - Haruki, Risa

AU - Kimura, Takuya

AU - Iwasaki, Hitomi

AU - Yamada, Kana

AU - Kamiyama, Ikuo

AU - Kohno, Mitsutomo

AU - Taguchi, Kazuaki

AU - Nagao, Saori

AU - Maruyama, Toru

AU - Otagiri, Masaki

AU - Komatsu, Teruyuki

PY - 2015/7/29

Y1 - 2015/7/29

N2 - A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core-shell structured hemoglobin-albumin cluster designated as "HemoAct", is an O 2 -carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125 I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.

AB - A hemoglobin (Hb) wrapped covalently by human serum albumins (HSAs), a core-shell structured hemoglobin-albumin cluster designated as "HemoAct", is an O 2 -carrier designed for use as a red blood cell (RBC) substitute. This report describes the blood compatibility, hemodynamic response, and pharmacokinetic properties of HemoAct, and then explains its preclinical safety. Viscosity and blood cell counting measurements revealed that HemoAct has good compatibility with whole blood. Intravenous administration of HemoAct into anesthetized rats elicited no unfavorable increase in systemic blood pressure by vasoconstriction. The half-life of 125 I-labeled HemoAct in circulating blood is markedly longer than that of HSA. Serum biochemical tests conducted 7 days after HemoAct infusion yielded equivalent values to those observed in the control group with HSA. Histopathologic inspections of the vital organs revealed no marked abnormality in their tissues. All results indicate that HemoAct has sufficient preclinical safety as an alternative material for RBC transfusion.

UR - http://www.scopus.com/inward/record.url?scp=84938152957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938152957&partnerID=8YFLogxK

U2 - 10.1038/srep12778

DO - 10.1038/srep12778

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 12778

ER -